Sarcomatoid Renal Cell Carcinoma, or Renal cell carcinoma with sarcomatoid dedifferentiation: Review of literature

Authors

  • Fadwa Oudad Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco
  • Rajaa Karam Department of Pathology, Ibn Rochd University Hospital, Casablanca, Morocco
  • Nezha Tawfiq Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco
  • Hassan Jouhadi Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco
  • Rachid Aboutaieb Department of Pathology, Ibn Rochd University Hospital, Casablanca, Morocco
  • Mehdi Karkouri Department of Pathology, Ibn Rochd University Hospital, Casablanca, Morocco
  • Mouna Bourhafour Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco
  • Zineb Bouchbika Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco
  • Nadia Benchakroun Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco
  • Souha Sahraoui Mohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco
  • Abdellatif Benider Department of Pathology, Ibn Rochd University Hospital, Casablanca, Morocco

Keywords:

sarcomatoid, prognosis, metastasis, immune checkpoint inhibitors

Abstract

Our understanding of the biology and pathophysiology of renal cell carcinoma (RCC) has greatly improved over the last decade. Understanding the disease process has helped us discover new histological subtypes and develop newer therapeutic approaches.
Although it is considered a histological subtype of all renal cell carcinomas (RCC), sarcomatoid renal cell carcinoma (sRCC) has been shown throughout the few cases found in the literature that it has a poorer prognosis and seems to not benefit from its historical 1st line treatment which is targeted agents such as sunitinib.
In this article, we will look at the characteristics of sarcomatoid renal cell carcinoma (sRCC) and how various drugs are currently used to treat it.
This article also examines the immune system's role in allowing sRCC growth and how the immune system can be manipulated to reactivate cytotoxic immunity against sRCC.
Indeed, the expansion of immunotherapies approved for sRCC has generated a search for biomarkers that might be indicative of treatment response in sarcomatoid RCCs (sRCCs), such as PDL1 expression, suggesting a potential benefit from PD1 and/or PDL1 immune checkpoint inhibitors.

Downloads

Published

2023-04-20

Issue

Vol. 1 No. 1: Current Issue

Section

Articles